TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (FDMT) (CEO: David Kirn, ...
A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial ...
Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5,with follow-up through 1 year at dose selected for Phase 2 Durable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback